Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research report report published on Friday morning,Benzinga reports.

Several other equities research analysts also recently weighed in on SAGE. Wedbush restated a “neutral” rating and set a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. Canaccord Genuity Group reduced their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, February 12th. Piper Sandler lowered their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. HC Wainwright restated a “neutral” rating and issued a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Scotiabank decreased their price objective on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating for the company in a research report on Wednesday, February 12th. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Sage Therapeutics has an average rating of “Hold” and a consensus price target of $8.81.

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $7.79 on Friday. The stock has a fifty day simple moving average of $7.52 and a 200-day simple moving average of $6.76. The stock has a market cap of $478.94 million, a PE ratio of -1.18 and a beta of 0.48. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $14.71.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Research analysts predict that Sage Therapeutics will post -3.52 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Several hedge funds have recently made changes to their positions in the business. US Bancorp DE raised its stake in Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 2,268 shares during the period. Teacher Retirement System of Texas lifted its stake in shares of Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 2,446 shares in the last quarter. Picton Mahoney Asset Management boosted its stake in shares of Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 3,581 shares during the last quarter. Geode Capital Management LLC boosted its stake in Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after acquiring an additional 3,757 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in Sage Therapeutics by 31.2% in the fourth quarter. ProShare Advisors LLC now owns 18,281 shares of the biopharmaceutical company’s stock worth $99,000 after purchasing an additional 4,350 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.